Radioligand therapies in meningioma: Evidence and future directions
Neuro-Oncology · 09.12.2024 · 26 (Supplement_9) · S215-S228
DOI: 10.1093/neuonc/noae069 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 04.05.2024. Verfasst von Maximilian J Mair und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grades 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after the exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters. Alongside this, integrated molecular imaging allows for a noninvasive assessment of predictive biomarkers as treatment targets. Whereas the concept of “theranostics” has initially evolved in extracranial tumors such as thyroid diseases, neuroendocrine tumors, and prostate cancer, data from retrospective case series and early phase trials underscore the potential of this strategy in meningioma. This review aims to explore the available evidence of radionuclide treatments and ongoing clinical trial initiatives in meningioma. Moreover, we discuss optimal clinical trial design and future perspectives in the field, including compound- and host-specific determinants of the efficacy of “theranostic” treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, GlioME Team, plateforme PETRA, CHU Timone, Service de Neurooncologie, Marseille, France.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone, New York, New York, USA.
- Department of Radiation Oncology, New York University Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Maximilian J Mair, Patrick Y Wen, Matthias Preusser
Zitieren
APA
Mair, M. J., Tabouret, E., Johnson, D. R., Sulman, E. P., Wen, P. Y., Preusser, M., & Albert, N. L. (2024). Radioligand therapies in meningioma: Evidence and future directions. Neuro-Oncology, 26(Supplement_9), S215-S228. https://doi.org/10.1093/neuonc/noae069
Vancouver
Mair MJ, Tabouret E, Johnson DR, Sulman EP, Wen PY, Preusser M, et al. Radioligand therapies in meningioma: Evidence and future directions. Neuro-Oncology. 2024;26(Supplement_9):S215-S228. doi:10.1093/neuonc/noae069
BibTeX
@article{Mair2024,
author = {Mair, Maximilian J and Tabouret, Emeline and Johnson, Derek R and Sulman, Erik P and Wen, Patrick Y and Preusser, Matthias and Albert, Nathalie L},
title = {Radioligand therapies in meningioma: Evidence and future directions},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {Supplement_9},
pages = {S215--S228},
doi = {10.1093/neuonc/noae069}
}
EUVIMED